Allianz Asset Management GmbH Raises Holdings in Inogen Inc (INGN)

Allianz Asset Management GmbH lifted its position in shares of Inogen Inc (NASDAQ:INGN) by 3.8% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 40,629 shares of the medical technology company’s stock after purchasing an additional 1,490 shares during the quarter. Allianz Asset Management GmbH owned about 0.19% of Inogen worth $3,864,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. increased its position in Inogen by 1.9% during the second quarter. BlackRock Inc. now owns 2,150,552 shares of the medical technology company’s stock valued at $205,207,000 after acquiring an additional 39,752 shares during the last quarter. Vanguard Group Inc. increased its position in Inogen by 24.9% during the second quarter. Vanguard Group Inc. now owns 1,515,342 shares of the medical technology company’s stock valued at $144,594,000 after acquiring an additional 301,737 shares during the last quarter. Koch Industries Inc. increased its position in Inogen by 19,485.8% during the second quarter. Koch Industries Inc. now owns 657,102 shares of the medical technology company’s stock valued at $650,000 after acquiring an additional 653,747 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Inogen by 3.4% during the second quarter. Dimensional Fund Advisors LP now owns 519,523 shares of the medical technology company’s stock valued at $49,572,000 after acquiring an additional 17,111 shares during the last quarter. Finally, State Street Corp increased its position in Inogen by 6.8% during the second quarter. State Street Corp now owns 425,662 shares of the medical technology company’s stock valued at $40,619,000 after acquiring an additional 27,250 shares during the last quarter.

Shares of Inogen Inc (NASDAQ INGN) traded up $0.42 during mid-day trading on Friday, reaching $115.59. The company’s stock had a trading volume of 177,929 shares, compared to its average volume of 135,002. Inogen Inc has a fifty-two week low of $62.69 and a fifty-two week high of $130.05. The stock has a market capitalization of $2,403.64, a P/E ratio of 93.98, a PEG ratio of 3.90 and a beta of 1.13.

Inogen (NASDAQ:INGN) last issued its quarterly earnings results on Tuesday, November 7th. The medical technology company reported $0.33 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.04. Inogen had a return on equity of 13.37% and a net margin of 11.36%. The firm had revenue of $69.00 million for the quarter, compared to the consensus estimate of $63.55 million. During the same period in the prior year, the business posted $0.25 earnings per share. The company’s revenue for the quarter was up 26.8% on a year-over-year basis. research analysts expect that Inogen Inc will post 1.19 earnings per share for the current year.

A number of research firms have recently weighed in on INGN. BidaskClub lowered Inogen from a “hold” rating to a “sell” rating in a research note on Saturday, January 6th. Needham & Company LLC upped their price objective on Inogen from $108.00 to $125.00 and gave the stock a “strong-buy” rating in a research note on Wednesday, November 8th. Zacks Investment Research raised Inogen from a “hold” rating to a “buy” rating and set a $131.00 price objective for the company in a research note on Thursday, November 9th. Finally, Leerink Swann reissued an “outperform” rating and set a $120.00 price target (up from $115.00) on shares of Inogen in a research note on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $102.71.

In other Inogen news, EVP Byron Myers sold 35,000 shares of the stock in a transaction on Friday, November 17th. The stock was sold at an average price of $116.77, for a total transaction of $4,086,950.00. Following the sale, the executive vice president now owns 48,600 shares of the company’s stock, valued at approximately $5,675,022. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ray Benjamin M. Anderson sold 1,000 shares of the stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $119.06, for a total value of $119,060.00. Following the sale, the director now directly owns 1,000 shares in the company, valued at approximately $119,060. The disclosure for this sale can be found here. Over the last quarter, insiders sold 81,500 shares of company stock worth $9,267,695. Company insiders own 5.31% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Allianz Asset Management GmbH Raises Holdings in Inogen Inc (INGN)” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/13/allianz-asset-management-gmbh-buys-1490-shares-of-inogen-inc-ingn.html.

Inogen Profile

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply